Apomorphine is a somewhat strange Dopamine Agonist (non-egoline DA Parky B!) that required subcutaneous injections. It certainly hasn't been a mainline DA prescription in the USA.
Sunovian developed back in 2012 a 2 part sublingual film that was applied under the tongue to reduce the difficulties of injection (and the resulting pain). They moved their new method and its application all the way up the chain of of CTs (Phase 1,2, and 3) eventually asking for FDA approval way back in 2018.
Apokyn's Apomorphine's approval by the FDA goes all the way back to 2004. So you would think the sublingual film would get a fast track, no problem approval. The FDA rejected their application in early 2019.
I don't understand the FDA's rejection and call for "more information". I surmise the FDA wanted information about whether or not the film was inferior/superior to the injection approach and why. Sunovian has not examined that issue probably for obvious reasons. Second, the number of different doses (6) and frequency of use (as many as 5 in 1 day) probably raised additional questions. Perhaps too many combinations. Third, The traditional application methodology raises some serious questions about this drug's bioavailability although the trial results were very encouraging.
Even with these concerns which are legitimate, APL-130277 clearly showed efficacy in reducing "off" periods in PD patients who had progressed to at least one "off" period of a significant duration and were using a significant amount of a L-Dopa drug. To me, the FDA seems a trifle too conservative on this application.